Tyrosine kinase inhibitors have improved outcomes in Philadelphia-positive ALL, but their efficacy in CNS disease remains uncertain. Ponatinib was studied for CNS distribution in 22 samples from 16 patients. CSF concentrations fell below the 40nM threshold, suggesting suboptimal CNS exposure.

Subjects:
Lymphoid Neoplasia
This content is only available as a PDF.
Copyright © 2024 American Society of Hematology
2024

Article PDF first page preview

Article PDF first page preview
You do not currently have access to this content.
Sign in via your Institution